Boston Scientific Corporation $BSX Shares Sold by Blue Trust Inc.

Blue Trust Inc. trimmed its position in Boston Scientific Corporation (NYSE:BSX) by 59.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,023 shares of the medical equipment provider’s stock after selling 2,977 shares during the quarter. Blue Trust Inc.’s holdings in Boston Scientific were worth $217,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of BSX. 1248 Management LLC acquired a new stake in shares of Boston Scientific in the 1st quarter valued at $26,000. Y.D. More Investments Ltd purchased a new position in shares of Boston Scientific in the 1st quarter valued at $27,000. Sound Income Strategies LLC grew its position in shares of Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 120 shares during the last quarter. Oliver Lagore Vanvalin Investment Group purchased a new position in shares of Boston Scientific in the 2nd quarter valued at $37,000. Finally, Activest Wealth Management grew its position in shares of Boston Scientific by 6,216.7% in the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after buying an additional 373 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Up 1.4%

Shares of NYSE:BSX opened at $96.26 on Wednesday. The company has a market cap of $142.63 billion, a price-to-earnings ratio of 57.30, a PEG ratio of 2.29 and a beta of 0.61. The firm’s 50-day simple moving average is $101.58 and its 200-day simple moving average is $101.80. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business’s quarterly revenue was up 22.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Activity

In related news, Director Edward J. Ludwig sold 4,000 shares of the firm’s stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director owned 18,479 shares in the company, valued at $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the firm’s stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the sale, the director owned 2,081 shares of the company’s stock, valued at $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock worth $17,972,457 in the last ninety days. 0.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on BSX shares. Truist Financial increased their target price on shares of Boston Scientific from $125.00 to $129.00 and gave the company a “buy” rating in a research report on Wednesday, October 1st. Erste Group Bank downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, October 8th. Leerink Partners increased their target price on shares of Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Finally, UBS Group raised their price objective on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, July 24th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $120.71.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.